A Phase I Trial of Oral Ridaforolimus (AP23573; MK-8669) in Combination with Bevacizumab for Patients with Advanced Cancers
John Nemunaitis(Gradalis (United States)), Monica Mita(Novartis (Switzerland)), Howard S. Höchster(Rutgers, The State University of New Jersey), Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States)), P. Dodion(Dana-Farber/Harvard Cancer Center), Christopher D. Turner(Ariadne Diagnostics (United States)), Rand R. Rhodes(Merck & Co., Inc., Rahway, NJ, USA (United States)), Stephanie Lustgarten(Ariadne Diagnostics (United States))
Cited by 13
Related Papers
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k